Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 11

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 8
Chunk 11
---
10 years and the exercise price of each option is determined by the independent members of the board of directors.

Options have been granted under the 2019 Plan allowing the holders to purchase Common Shares of the Company as follows:

			Number of Options (#)

			Weighted Average Exercise Price

			Weighted Average Grant Date Fair Value

			Nine Months Ended June 30, 2025

			Balance - September 30, 2024

			383,040

			$
			24.93

			$
			18.33

			Forfeited

			(4,431
			)

			25.20

			17.69

			Expired

			(374
			)

			246.96

			246.96

			Balance - June 30, 2025

			378,235

			$
			24.71

			$
			18.11

			Nine Months Ended June 30, 2024

			Balance - September 30, 2023

			420,615

			$
			25.60

			$
			18.84

			Granted

			500

			4.10

			3.10

			Forfeited

			(2,401
			)

			15.00

			10.70

			Expired

			(35,674
			)

			33.18

			24.63

			Balance - June 30, 2024

			383,040

			$
			24.93

			$
			18.33

13

During the three and nine months ended June 30, 2025, there were no employee or director options granted. During the three and nine months ended June 30, 2024, there were 500 employee options granted and no director options granted. The options have a term of 10 years and an exercise price equal to the Nasdaq closing price on the grant date.

The weighted average contractual life remaining on the outstanding options at June 30, 2025 is 72 months.

The following table summarizes information about the options under the 2019 Plan outstanding and exercisable at June 30, 2025:

			Number of Options (#) 

			Exercisable at
			J